(Adds detail in paragraphs 3 and 4) LONDON, April 24 (Reuters) - Consumer goods group Reckitt's like-for-like sales growth beat estimates in the first quarter as more people bought its Lysol, Dettol and Finish cleaning products even as prices rose. The company said it was on track to meet full-year revenue and profit targets, led by mid-single-digit growth across its health and hygiene businesses. Reckitt's quarterly like-for-like net sales rose 1.5%, ahead of the 0.9% growth analysts had expected in a company-supplied poll. "We continue to benefit from carryover pricing and consumers trading up to our premium innovations," CEO Kris Licht said. Reckitt's other products include Nurofen tablets, cold remedy Lemsip and Durex condoms. (Reporting by Richa Naidu Editing by David Goodman and Ros Russell)
UPDATE 5-Reckitt beats like-for-like sales estimates, driven by Dettol, Lysol
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...